ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Homoisoflavanone Delays Colorectal Cancer Progression via DNA Damage-Induced Mitochondrial Apoptosis and Parthanatos-Like Cell Death.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Yiyi Fuzi Baijiang formula protects against DSS-induced colitis by orchestrating the gut barrier-microbiota-metabolism axis.Chinese medicine · 2026Article
- Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.Pharmaceutics · 2026Review
- Phytochemistry, Biological Synthesis, and Pharmacology of Flavonoids from GenusMolecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Colorectal cancer remains a major global health challenge, particularly in advanced stages where current therapies show limited efficacy. Natural products, specifically those derived from herbal medicines, provide a valuable resource for discovering novel anticancer agents. In this study, a bioactive homoisoflavanone was successfully isolated and structurally characterized from Polygonatum kingianum, a widely used medicinal herb. In vitro, homoisoflavanone exhibited potent antiproliferative and pro-apoptotic effects in colorectal cancer cells. Mechanistically, homoisoflavanon induced DNA damage mediated mitochondrial apoptosis and parthanatos-like cell death, accompanied by ATM/ATR-Chk1 pathway and PARP activation, loss of mitochondrial membrane potential, elevated ROS levels, and ATP depletion. In vivo, homoisoflavanone significantly suppressed tumor growth in a colorectal cancer xenograft model without inducing systemic toxicity. Immunohistochemical analysis further confirmed decreased proliferation, increased apoptosis, and parthanatos-like cell death in tumor tissues. Collectively, these findings establish homoisoflavanone as a promising plant-derived therapeutic candidate that targets DNA integrity and mitochondrial homeostasis to inhibit colorectal cancer progression, highlighting the potential of herbal medicine-based compounds in anticancer drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.